Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a prescription "Helicobacter Pylori" combi-pack. It typically contains a combination of **Esomeprazole** (a proton pump inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is designed as a treatment regimen for the eradication of *H. pylori* infections.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease or chronic gastritis to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
Standard regimen (varies by regional formulation, verify local packaging):
* **Esomeprazole:** 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Duration:** Typically dosed for 7 to 14 days.
* *Note:* Ensure compliance with the specific blister pack instructions provided by the manufacturer.
## Pediatric Dosing
**Not indicated for routine pediatric use.** Safety and efficacy have not been established for *H. pylori* eradication in patients <18 years. Use in children should be deferred to a pediatric infectious disease specialist.
## Dose Adjustments
* **Renal Impairment:** No adjustment for Esomeprazole. Amoxicillin requires dosage reduction in severe renal impairment (CrCl <30 mL/min). Clarithromycin adjustment is required if CrCl <30 mL/min.
* **Hepatic Impairment:** Use caution with Clarithromycin and Esomeprazole; severe hepatic impairment may require dosage limits.
## Contraindications
* Known hypersensitivity to Esomeprazole, any substituted benzimidazole, Amoxicillin, any penicillin, or Clarithromycin (or any macrolide).
* Concurrent use with pimozide, cisapride, ergotamine, or dihydroergotamine due to risk of serious cardiac arrhythmias (Clarithromycin interaction).
* History of cholestatic jaundice or hepatic dysfunction associated with prior Clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, dysgeusia (metallic taste), and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis), QT interval prolongation (Clarithromycin), and hepatic enzyme elevation.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent inhibitor of CYP3A4 and may increase serum levels of drugs like statins (e.g., simvastatin/atorvastatin—risk of rhabdomyolysis), warfarin, and colchicine.
* **pH-Dependent Drugs:** Esomeprazole significantly increases gastric pH; may decrease absorption of drugs like atazanavir, ketoconazole, or iron salts.
* **Methotrexate:** PPIs may increase serum methotrexate levels.
## Monitoring
* Monitor for signs of *C. difficile* infection (persistent diarrhea).
* Assess for resolution of symptoms and confirm *H. pylori* eradication via breath testing, fecal antigen testing, or endoscopy at least 4 weeks after therapy completion.
* Monitor cardiac rhythm in patients at risk for QT prolongation.
## Clinical Pearls
* **Compliance:** Stress the importance of completing the full course to prevent antibiotic resistance.
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal for optimal absorption.
* **Resistance:** Clarithromycin resistance is rising globally. If local resistance rates exceed 15%, quadruple therapy (bismuth, tetracycline, metronidazole, PPI) is often preferred over this triple therapy regimen. Consult local antibiograms.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines change. Always verify current prescribing information, local resistance patterns, and institutional protocols before administering or prescribing any medication. Consult the current package insert or a clinical pharmacist for the most recent updates.
